Nothing Special   »   [go: up one dir, main page]

IN2015DN02008A - - Google Patents

Info

Publication number
IN2015DN02008A
IN2015DN02008A IN2008DEN2015A IN2015DN02008A IN 2015DN02008 A IN2015DN02008 A IN 2015DN02008A IN 2008DEN2015 A IN2008DEN2015 A IN 2008DEN2015A IN 2015DN02008 A IN2015DN02008 A IN 2015DN02008A
Authority
IN
India
Prior art keywords
disease
diseases
diabetes
compounds
disorders
Prior art date
Application number
Inventor
Dinesh Barawkar
Anish Bandyopadhyay
Robert Zahler
Robindro Sarangthem
Yogesh Waman
Rajesh Bonagiri
Dilip Jadhav
Partha Mukhopadhyay
Original Assignee
Advinus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advinus Therapeutics Ltd filed Critical Advinus Therapeutics Ltd
Priority to IN2008DEN2015 priority Critical patent/IN2015DN02008A/en
Publication of IN2015DN02008A publication Critical patent/IN2015DN02008A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

The present invention relates to substituted fused tricyclic compounds of formula (I) their tautomers polymorphs stereoisomers prodrugs solvates co crystals pharmaceutically acceptable salts pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity.[Formula I should be inserted here]. The compounds of the present invention are useful in the treatment prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include but not limited to arthritis Alzheimer s disease autoimmune thyroid disorders cancer diabetes leukemia T cell prolymphocytic leukemia lymphoma myleoproliferation disorders lupus multiple myeloma multiple sclerosis osteoarthritis sepsis psoriatic arthritis prostate cancer T cell autoimmune disease inflammatory diseases chronic and acute allograft transplant rejection bone marrow transplant stroke asthma chronic obstructive pulmonary disease allergy bronchitis viral diseases or Type I diabetes complications from diabetes rheumatoid arthritis asthma Crohn s disease dry eye uveitis inflammatory bowel disease organ transplant rejection psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds and to pharmaceutical compositions containing them.
IN2008DEN2015 2012-09-21 2013-09-18 IN2015DN02008A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2008DEN2015 IN2015DN02008A (en) 2012-09-21 2013-09-18

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3940CH2012 2012-09-21
IN2008DEN2015 IN2015DN02008A (en) 2012-09-21 2013-09-18
PCT/IN2013/000564 WO2014045305A1 (en) 2012-09-21 2013-09-18 Substituted fused tricyclic compounds, compositions and medicinal applications thereof

Publications (1)

Publication Number Publication Date
IN2015DN02008A true IN2015DN02008A (en) 2015-08-14

Family

ID=54256401

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2008DEN2015 IN2015DN02008A (en) 2012-09-21 2013-09-18

Country Status (5)

Country Link
US (1) US9593115B2 (en)
EP (1) EP2897962A1 (en)
JP (1) JP2015529242A (en)
IN (1) IN2015DN02008A (en)
WO (1) WO2014045305A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
DK3169315T3 (en) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
CN105983097B (en) * 2015-01-28 2021-06-08 华中科技大学同济医学院附属协和医院 Anti-tumor preparation and preparation method thereof
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
US11292791B2 (en) 2017-09-15 2022-04-05 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
CN116178369A (en) 2018-06-29 2023-05-30 福马疗法公司 Inhibition of CREB Binding Protein (CBP)
CR20210175A (en) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN111548408B (en) * 2018-10-30 2021-08-03 德琪(浙江)医药科技有限公司 Improved tumor inhibiting peptide capable of being specifically combined with PD-1 and application thereof
CN109608457B (en) * 2019-01-21 2020-05-12 牡丹江医学院 Medicine for treating pneumonia and preparation method thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
WO2021247969A1 (en) 2020-06-05 2021-12-09 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4666762B2 (en) 1998-06-19 2011-04-06 ファイザー・プロダクツ・インク Pyrrolo [2.3-d] pyrimidine compounds
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
UA74370C2 (en) 2000-06-26 2005-12-15 Пфайзер Продактс Інк. Pyrrole(2,3-d)pyrimidine compounds as immunosuppressors
AU2003210983A1 (en) 2002-02-11 2003-09-04 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
PL378246A1 (en) 2002-11-26 2006-03-20 Pfizer Products Inc. Method of treatment of transplant rejection
DE60326646D1 (en) 2002-12-18 2009-04-23 Vertex Pharma BENZINE OXAZOLE DERIVATIVES PROPER AS INHIBITORS OF PROTEIN KINASES
SE0301372D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
JP2007521301A (en) 2003-07-02 2007-08-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ CCK-1 receptor modulator
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
CN1893952A (en) 2003-12-17 2007-01-10 辉瑞产品公司 Pyrrolo[2,3-D]pyrimidine compounds for treating transplant rejection
AR048454A1 (en) 2004-03-30 2006-04-26 Vertex Pharma USEFUL AZAINDOLS AS INHIBITORS OF JAK PROTEIN KINES OR OTHER KINASE PROTEINS
WO2005105788A1 (en) 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP2386856B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
JP5227032B2 (en) 2005-02-03 2013-07-03 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrrolopyrimidines useful as inhibitors of protein kinases
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
PT2348023E (en) 2005-12-13 2015-09-15 Incyte Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
TWI424999B (en) 2006-01-17 2014-02-01 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
MX2008012860A (en) 2006-04-05 2009-01-07 Vertex Pharma Deazapurines useful as inhibitors of janus kinases.
TWI398252B (en) 2006-05-26 2013-06-11 Novartis Ag Pyrrolopyrimidine compounds and their uses
EP2123651A4 (en) * 2007-01-12 2011-05-04 Astellas Pharma Inc Condensed pyridine compound
WO2009054941A1 (en) 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
WO2009071701A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
TWI449703B (en) * 2008-06-10 2014-08-21 Abbvie Inc Novel tricyclic compounds
CA2727928A1 (en) 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
CN101723936B (en) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 Kinase suppressor and pharmaceutical application thereof
WO2010085684A1 (en) 2009-01-23 2010-07-29 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2758359A1 (en) * 2009-04-14 2010-10-21 Astellas Pharma Inc. Fused pyrrolopyridine derivative
WO2011003418A1 (en) 2009-07-08 2011-01-13 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
US8945551B2 (en) 2009-07-09 2015-02-03 Polymers Crc Ltd. Biopolymer hybrid gel-depot delivery system
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
RU2711869C3 (en) 2009-12-01 2022-02-02 Эббви Инк. Imidazopyrrolopyrazine derivatives useful in the treatment of diseases caused by abnormal activity of Jak1, Jak3 or Syk protein kinases
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors

Also Published As

Publication number Publication date
EP2897962A1 (en) 2015-07-29
US9593115B2 (en) 2017-03-14
JP2015529242A (en) 2015-10-05
WO2014045305A1 (en) 2014-03-27
US20150239886A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
IN2015DN02008A (en)
IN2012CH01573A (en)
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
PH12018502364A1 (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
MX2019005306A (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors.
EA200970852A1 (en) PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PHOSPHODESTERASE INHIBITORS
MX2016017030A (en) Mnk inhibitors and methods related thereto.
PH12015501199B1 (en) Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
IL295229A (en) Process for reclamation of polyester by reactor addition
WO2016181408A3 (en) NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST
EA201490357A1 (en) INTRODUCTION
IN2014DN07885A (en)
MX2019005233A (en) Pyrrole amides as alpha v integrin inhibitors.
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
RU2018112961A (en) Cyanothienotriazolodiazepine AND WAYS OF THEIR APPLICATION
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
MX2017005281A (en) Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX2010011464A (en) 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors.
MX2023009372A (en) Process for the preparation of drug linker compounds.
CO6630197A2 (en) New process
MX2016012007A (en) Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use.
MX2016009624A (en) Novel heterobicyclic compounds as kappa opioid agonists.
SG11202007723UA (en) Regulation of process stream composition for improved electrolyzer performance